Clinical trials: Desmoid Tumors
Desmoid Fibromatosis
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis.
- Trial name
- NCT02066181
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib Tosylate
- Where
- 150 sites in United States, Canada
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Desmoid-type Fibromatosis
Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients
This is a prospective, multicenter observational study under the umbrella of the ISG (Italian Sarcoma Group) evaluating local progression-free survival at 3 years of patients affected by extra-abdominal primary fibromatosis…
- Trial name
- NCT02547831
- Testing
- Observational approach
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Desmoid
Arterial Chemoembolization for the Treatment of Desmoid Fibromatosis
Desmoid fibromatoses are rare (1-2 cases/million per year) and locally aggressive mesenchymal tumors. For asymptomatic disease, current guidelines suggest an initial period of active surveillance.
- Trial name
- Embodesmo (NCT06268457)
- Testing
- Chemoembolization with Doxorubicin
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Ortopedico Rizzoli
Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
The purpose of this study is to collect and store tumor tissue, blood, and bone marrow samples from patients with soft tissue sarcoma that will be tested in the laboratory.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Chordoma, Desmoid-Type Fibromatosis
- Trial name
- NCT00919269
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- 247 sites in United States, Australia and 5 more
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Dermoid
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy
- Trial name
- MP-VAC-206 (NCT06219733)
- Testing
- Vactosertib, Imatinib
- Where
- South Korea
- Sponsor
- MedPacto, Inc.
Soft Tissue Sarcoma, Desmoid Tumors
HIFU Ablation of Soft Tissue Sarcoma
Around 3,300 people are diagnosed with soft tissue sarcoma (STS) each year in the UK, and a significant proportion of STS diagnoses are in people aged under 30 years.
- Trial name
- SarcAblate (NCT05111964)
- Testing
- High Intensity Focused Ultrasound Ablation, Tumour Biopsy and Venous Blood Tests
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Oxford University Hospitals NHS Trust
Desmoid Tumor, Desmoid Fibromatosis
A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors
This is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors. In the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated…
- Conditions
- Desmoid Tumor, Desmoid Fibromatosis, Desmoid
- Trial name
- RFAdesmoid (NCT06355921)
- Testing
- radiofrequency ablation
- Where
- Russia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center
Desmoid Tumor
Study of Cryoablation and Nirogacestat for Desmoid Tumor
The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.
- Trial name
- NCT05949099
- Testing
- Nirogacestat, Cryoablation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Nam Bui
Desmoid Tumor
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
This phase II trial is studying how well giving sulindac together with tamoxifen works in treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell…
- Trial name
- NCT00068419
- Testing
- tamoxifen citrate, sulindac, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Children's Oncology Group
Desmoid Tumor
Radiation Therapy in Treating Patients With Aggressive Fibromatoses
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients who have aggressive fibromatoses.
- Trial name
- NCT00030680
- Testing
- radiation therapy
- Where
- 21 sites in Belgium, France and 5 more
- Volunteers
- 44 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Progressive Desmoids Tumors
PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Desmoids tumors are benign soft tissues tumors characterized by aggressiveness and potential local recurrence. There is a female predominance with a sex ratio of 2/1 and median age at diagnosis is about 30 years.
- Trial name
- DESMOPAZ (NCT01876082)
- Testing
- PAZOPANIB treatment, Active Comparator: Vinblastine and Methotrexate
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Institut Bergonié
Aggressive Fibromatosis, Desmoid Tumor
Study to Evaluate Imatinib in Desmoid Tumors
The objective of the present study is to evaluate the activity and safety of imatinib in patients with aggressive fibromatosis who, after receiving the standard therapy, show an inoperable recurrent tumor or disease not readily…
- Trial name
- NCT01137916
- Testing
- Imatinib
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- Heidelberg University
Desmoid Tumor, Aggressive Fibromatosis
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive…
- Trial name
- DeFi (NCT03785964)
- Testing
- Nirogacestat oral tablet
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 142 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Desmoid Tumor
Toremifene in Treating Patients With Desmoid Tumors
RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using toremifene may fight the growth of desmoid tumors by reducing the production of estrogen.
- Trial name
- NCT00002595
- Testing
- toremifene, conventional surgery
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Advocate Lutheran General Hospital
Cancer
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
- Trial name
- PALANGI3 (NCT01046487)
- Testing
- Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- Where
- 3 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Oscar Lambret
Hormone Receptor-Positive Breast, Gynecologic
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Background: Some types of cancer cells that have hormone receptors on their surfaces need the hormone estrogen to grow. The drug tamoxifen blocks estrogen from binding to the tumor cells, which helps to slow or stop the growth of…
- Conditions
- Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
- Trial name
- NCT01273168
- Testing
- Z-Endoxifen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)